Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer-Reference-Cited by-同舟云学术

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer

Published:2016-09-12 Issue:50 Volume:7 Page:82185-82199
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Queralt Bernardo¹²³,Cuyàs Elisabet²⁴,Bosch-Barrera Joaquim¹²,Massaguer Anna⁵,de Llorens Rafael⁵,Martin-Castillo Begoña²⁶,Brunet Joan¹²³,Salazar Ramon⁷,Menendez Javier A.²⁴

Affiliation:

1. Department of Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain

2. Girona Biomedical Research Institute, Girona, Catalonia, Spain

3. Department of Medical Sciences, Medical School, University of Girona, Girona, Spain

4. ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism & Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain

5. Biochemistry and Molecular Biology Unit, Department of Biology, University of Girona, Girona, Spain

6. Unit of Clinical Research, Catalan Institute of Oncology, Girona, Catalonia, Spain

7. Department of Medical Oncology, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Translational research of new developments in targeted therapy of colorectal cancer;Pathology - Research and Practice;2023-12

2. Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer;The Oncologist;2023-09-29

3. Potential drug–drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma;Expert Opinion on Drug Metabolism & Toxicology;2023-08-03

4. KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics;Critical Reviews in Oncology/Hematology;2023-06

5. Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer;Journal of Clinical Medicine;2022-12-19